TheraBionic — Amplitude-Modulated RF (Tumour-Specific Frequencies)

TheraBionic is a handheld device that delivers amplitude-modulated 27.12 MHz radiofrequency through a spoon-shaped antenna held in the mouth, at a set of frequencies said to be specific to hepatocellular carcinoma. It sits in the Electromagnetic family for a reason that makes it the most interesting entry in this atlas: it is the one “frequency oncology” device with both a published molecular mechanism and a regulatory clearance. That is precisely what the Rife tradition claims and does not have. But a mechanism and a clearance are not the same as proven efficacy, and this page is the worked example of that distinction.

Mechanism — a real, published molecular target

Unlike the “mortal oscillatory rate” of the Rife doctrine, TheraBionic's proposed mechanism was characterised and peer-reviewed. Amplitude-modulated RF at tumour-specific modulation frequencies was reported to raise intracellular calcium through Ca_v3.2 (CACNA1H) T-type voltage-gated calcium channels in hepatocellular-carcinoma cells specifically, pushing them toward differentiation rather than proliferation, with a pronounced effect on cancer stem cells (Jimenez et al., EBioMedicine 2019). This is a named channel, a named cell type, and a defined signalling pathway — a genuine mechanism, not a metaphor. It is the single fact that separates this device from the rest of “frequency medicine.”

Claim vs evidence — why C, and why not higher

The clinical base is thin. The pivotal-style evidence is a phase I/II study of just 13 patients (Barbault/Pasche, 2009) plus a pooled real-world cohort compared against a historical control — median overall survival in Child-Pugh A patients of 10.36 vs 7.74 months (p = 0.036). There is no pivotal randomized controlled trial. A survival signal against a historical, non-randomized comparator is hypothesis-generating, not confirmatory. That is what grade C encodes: a real mechanism and a suggestive, but not controlled, clinical result.

HDE is not PMA — reading the clearance correctly

In September 2023 the FDA authorised the TheraBionic P1 under a Humanitarian Device Exemption (HDE H220001) for advanced hepatocellular carcinoma unresponsive to other treatment (FDA). An HDE is reviewed under a “probable benefit” standard for rare conditions — it is explicitly not the premarket-approval (PMA) effectiveness standard that a full efficacy claim requires. The device is CE Class IIa (2018) and holds an FDA Breakthrough Device designation (2019). In this atlas's grammar, that is market access and regulatory encouragement — not demonstrated survival benefit. Registration is never efficacy, and the humanitarian route says so in its own name.

The contrast that defines the entry

Place TheraBionic on the family's evidence ladder and it lands in the middle by design. Above it, TTFields reached the market on a positive phase III survival RCT (PMA) — same broad idea (an applied electromagnetic field acting on cancer cells), opposite evidentiary maturity. Below it, the Rife machine claims a curative frequency mechanism with no published pathway and no controlled data at all. TheraBionic is the honest middle: a published mechanism, a real registration, and clinical data that are simply not yet strong enough to call it proven. It is the legitimate cousin the Rife tradition points to but never becomes.

Keep vs set aside

Keep: a peer-reviewed molecular mechanism (Ca_v3.2 calcium influx in HCC), a humanitarian clearance, and a suggestive survival signal. Set aside: the reading that any of this proves efficacy. There is no pivotal RCT; the HDE is a probable-benefit route, not a PMA; the survival comparison is against a historical control. The mechanism earns the device its place in the evidence tier rather than behind a contradicts-physics badge — and the missing randomized trial is exactly why the tier is Insufficient, not Evidence-supported.